CSF3 and ischemic stroke: Recombinant Csf3 partially reversed LJP's protective effects, while Csf3-specific antibodies failed to enhance LJP's anti-inflammatory benefits, suggesting Csf3 as an important contributory mechanism.<h4>Discussion</h4>These findings demonstrate that LJP mitigates acute neuroinflammation post-I/R at least partly through Csf3 suppression, highlighting its promise as a novel phytotherapeutic agent for ischemic stroke.